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Abstract
Chemotherapy resistance frequently drives tumour progression. However, the underlying
molecular mechanisms are poorly characterized. Epithelial-to-mesenchymal transition (EMT) has
been shown to correlate with therapy resistance, but the functional link and signalling pathways
remain to be elucidated. We report here that miR-30c, a human breast tumour prognostic marker,
plays a pivotal role in chemo-resistance by a direct targeting of TWF1, which encodes an actin-
binding protein and promotes EMT. An IL-6 family member, IL-11 was identified as a secondary
target of TWF1 in the miR-30c signalling pathway. Expression of miR-30c inversely correlated
with TWF1 and IL-11 levels in primary breast tumours and low IL-11 correlated with relapse-free
survival in breast cancer patients. Our study demonstrates that miR-30c is transcriptionally
regulated by GATA3 in breast tumours. Identification of a novel miRNA-mediated pathway that
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regulates chemo-resistance in breast cancer will facilitate the development of novel therapeutic
strategies.
Introduction
Therapy resistance, whether intrinsic or acquired, is one of the most fundamental problems
in cancer and contributes to local and distant tumour recurrence and disease progression. A
better understanding of the underlying molecular mechanisms will undoubtedly lead to the
development of more effective therapies. Non-coding single-stranded microRNAs
(miRNAs, miRs) have emerged as important epigenetic regulators of protein coding genes
and aberrant miRNA expression has been found in many cancers1. However, the role of
miRNAs in chemo-resistance remains to be characterized. In addition, the epithelial-to-
mesenchymal transition (EMT) has been connected to breast cancer chemo-resistance2,3 but
the regulatory link is unknown. We therefore hypothesized that miRNAs that regulate EMT
might be critical for regulating drug resistance. MiRNAs inhibit target genes primarily by
degrading mRNA or by repressing translation via seed sequence-mediated imperfect,
complementary binding to 3’ untranslated regions (3’UTRs)4,5. By combining microarray
analyses, miRNA target prediction algorithms, and experimental validation approaches, we
sought to identify miRNA targets that regulate EMT and drug resistance in breast cancer
cells.
Results
miR-30c is a prognostic biomarker in breast cancer
To identify miRNA biomarkers, we profiled primary breast tumour miRNA expression
levels and performed clinicopathologic correlation analyses for breast tumours collected
under IRB approved protocols at the University of Chicago Breast SPORE and in
independent datasets.
Frozen primary breast tumour tissues (University of Chicago [UC] tumour set, n=46) and
adjacent normal tissues (n=5) were first profiled for both gene and miRNA expression. 152
of 757 expressed miRNAs passed the filtering criteria for subsequent unsupervised
hierarchical clustering (Fig. 1a; see also patient information in Supplementary Table S1).
Unsupervised clustering divided the miRNAs into Cluster A and Cluster B, and these
miRNAs displayed distinct expression patterns in the UC breast tumour set. Specifically,
Cluster A miRNAs were up regulated in Group One tumours and Cluster B miRNAs were
up regulated in Group Two tumours.
The hsa-miR-30 family segregated with the Cluster B miRNAs with high expression in
Group Two patient tumours, including many known tumour-suppressor-miRs such as the
let-7 family members (Fig. 1a). To determine the role of the miR-30 family members in
breast cancer progression, we first examined their clinical relevance for patient survival. In
an independent Oxford breast tumour dataset containing a retrospective series of 10-year
follow up cases (n=210) with matched miRNA and mRNA expression arrays (GSE 22216
and GSE22220 respectively)6, we identified miR-30c as well as miR-30a, −30a*, and −30e*
as individual favourable breast cancer prognostic markers for distant relapse-free survival
(DRFS) (Fig. 1b–f). The prognostic role of miR-30c is still significant even when adjusted
for age, tumour size, ER status, nodal status, and histological grade (Supplementary Table
S2). Furthermore, when breast tumour subtypes are classified based on the PAM50 subtype
predictor7 and the 9 Cell Line Claudin-low predictor8, miR-30c expression is associated
with breast tumour subtypes in two independent datasets (UC tumour set and Oxford tumour
set6) (Supplementary Fig. S1a–c) and its prognostic role is subtype-dependent (Table S3).
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However, the miR-30c levels were not significantly different between paired primary breast
tumours and normal breast tissue adjacent to tumours (Supplementary Table S4).
By univariate analysis of a previous report, both miR-30a* and miR-30c have been shown to
correlate with the benefit of tamoxifen treatment and longer progression free survival in
oestrogen receptor (ER)-positive breast cancer patients9. However, in that study miR-30c
was the only independent miRNA predictor of tamoxifen treatment response by multivariate
analysis when adjusted for other clinico-phathologic factors9. We hypothesized that the
miR-30 family, especially miR-30c, might functionally regulate therapy response in addition
to having an association with treatment benefits. We therefore focused on their role in
chemo-resistance regulation in breast cancer.
miR-30c regulates chemo-resistance of breast cancer cells
To test our hypothesis that miR-30c plays a role in breast tumour progression and chemo-
resistance, we investigated the relevance of miR-30c to chemotherapy-induced cytotoxicity
of tumour cells. Interestingly, for six breast cancer cell lines (T47D, MCF-7, MDA-MB-231,
BT-20, HCC-70, and HCC-38), we observed a significant inverse correlation between
miR-30c levels and cell survival in response to paclitaxel (0.1–50 nM) and doxorubicin (1–
500 nM) treatments, represented as Log2-transformed expression levels and AUC (the Area
Under the survival Curve, in a series of 6 treatment doses) (Fig. 2a–b, p=0.04). These
correlations are more significant at the highest doses of paclitaxel (50 nM) and doxorubicin
(500 nM) (Supplementary Fig. S2a–b and Table S5, p=0.0198 and 0.0191 respectively).
We further characterized the role of miR-30c in regulating chemotherapy resistance by
modulating its levels in breast cancer cells. Transient transfection of miR-30c resulted in a
significant decrease in survival of chemo-resistant MDA-MB-231 breast cancer cells to
paclitaxel (Taxol, 0.5–10 nM) and doxorubicin (10–100 nM) at even low doses (Fig. 2c–e).
Growth curve analyses suggested that increased miR-30c levels did not affect cancer cell
growth (Fig. 2f). Elevated miR-30c also sensitized the drug response of a second breast
cancer cell line BT-20 to paclitaxel and doxorubicin (Fig. 2g). Furthermore, DNA content
analysis confirmed that miR-30c significantly increased the apoptotic sub-G1 population of
these cancer cells upon paclitaxel and doxorubicin treatments (Fig. 2h).
We also examined the effects of two other individual favourable breast cancer prognostic
markers in the miR-30 family, miR-30a and −30a*, on the response of MDA-MB-231 breast
cancer cells to chemotherapy drugs. While ectopic miR-30a did not show any effect on
doxorubicin treatment at various doses up to 200 nM, it did decrease breast cancer cell
survival in response to paclitaxel at very high doses (50 nM) (Supplementary Fig. S3a–b). In
addition, miR-30a* sensitized the drug response of breast cancer cells to doxorubicin (200
nM) and paclitaxel (5–50 nM) at relatively high doses (Supplementary Fig. S3a–b).
miR-30c regulates EMT and targets cytoskeleton gene TWF1
To examine the molecular mechanisms by which miR-30c regulates chemo-resistance, we
investigated its target genes and focused on a few that relate to EMT regulation and cancer
progression. Mammalian miRNAs regulate target genes primarily by decreasing mRNA
levels10. Multiple computational algorithms, such as GeneSet2miRNA which identifies
miRNA activities by at least four of eleven established miRNA target prediction
programs11, can predict potential interactions between genes and miRNAs. To strategically
identify direct miR-30c target genes, we used global transcriptome analysis (microarray) in
combination with GeneSet2miRNA and experimental validation analyses, including
immunoblots, luciferase assays, and functional rescue studies.
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We first performed microarray analyses of MDA-MB-231 cells that were transiently
transfected either with miR-30c oligos or the scrambled control. High miR-30c levels
significantly inhibited the expression levels of 291 genes in many networks and pathways,
such as anti-apoptosis and cytoskeleton genes (Fig. 3a; see also Supplementary Dataset 1).
Using this list, we performed online GeneSet2miRNA11 target gene prediction analysis and
narrowed the direct targets of miR-30c down to 77 potential genes, predicted by a minimum
of 4 out of 11 established algorithms (Fig. 3a; see also Supplementary Table S6). Among
these, the cytoskeleton genes twinfilin 1 (TWF1, also known as PTK9) and vimentin (VIM)
were reported to regulate cell motility, drug sensitivity, and cancer progression2,12–15.
The function of TWF1 as a regulator of drug sensitivity was previously revealed by in vivo
RNAi screening in a lymphoma model, along with other regulators of actin dynamics, such
as Rac212. TWF1 is a conserved actin-binding protein with two actin depolymerizing factor
homology (ADF-H) domains16 and belongs to the ADF-H family along with ADF/cofilin,
Abp1/drebrin, coactosin, and GMF17. It regulates diverse morphological and motile
processes by both sequestering ADP-actin monomers and capping filament barbed ends18,19.
We hypothesized that TWF1 is an important target of miR-30c by linking drug resistance to
actin-based cytoskeletal organization, such as the stress fiber F-actin, an EMT marker. To
address this hypothesis, we performed experimental validation analyses. Inhibition of TWF1
expression by miR-30c was confirmed in MDA-MB-231 cells by real-time PCR and western
blots (Fig. 3b–c). In addition, transient transfection of an anti-miR-30c inhibitor increased
TWF1 expression in these breast cancer cells (Fig. 3b). We also observed inhibitory effects
of miR-30c on the EMT markers VIM and SNAI2 at protein levels compared to the
scrambled miRNA control or a mock transfection control of MDA-MB-231 cells (Fig. 3c).
Accordingly, elevated miR-30c promoted a round epithelial cell phenotype and reduced the
stress fiber F-actin formation in MDA-MB-231 cells (Fig. 3d; large images in
Supplementary Fig. S4). Further analyses and quantitative counting of stained vinculin
revealed a reduction in focal adhesions, which further validated the effect of miR-30c on F-
actin dynamics (Supplementary Fig. S5a–b).
We then investigated whether TWF1 is a direct target of miR-30c. The functional interaction
between miR-30 and the 3’UTR of TWF1 was examined in luciferase assays in HEK293T
cells. Compared to the scrambled control, co-transfected miR-30c suppressed the expression
of the luciferase gene, which was located upstream of the wild type 3’UTR of TWF1 (Fig.
3e; see also Supplementary Fig. S6). Mutation of all three predicted recognition sites within
the 3’UTR of TWF1 (Supplementary Fig. S6) abolished the inhibitory effect of miR-30c on
luciferase activity (Fig. 3e). These data indicate that the inhibitory function of miR-30c on
the target gene requires interaction with the predicted binding sites.
TWF1 is important in regulating chemo-resistance and EMT
To determine the importance of TWF1 in miR-30c–regulated drug resistance, we performed
functional rescue assays by co-transfecting 3’UTR-deficient TWF1 cDNA and miR-30c in
MDA-MB-231 cells. While miR-30c expression induced inhibitory effects on chemo-
resistance, recombinantly expressed TWF1 (resistant to miR-30 inhibition) reversed
miR-30c–mediated sensitivity of the cancer cells to doxorubicin and paclitaxel (Fig. 4a).
Equally important, knockdown of TWF1 by siRNAs copied the phenotype of high miR-30c
levels by sensitizing breast tumour cells to chemotherapeutic agents doxorubicin and
paclitaxel at 100nM and 10nM treatment doses respectively (Fig. 4b–c).
We further investigated the effect of TWF1 knockdown on F-actin formation in MDA-
MB-231 cells. Notably, siRNAs of TWF1 dramatically inhibited F-actin organization,
reduced vinculin-stained focal adhesions, and promoted the mesenchymal-to-epithelial
Bockhorn et al. Page 4













transition (MET) with a round cell shape (Fig. 4d; see also Supplementary Fig. S4 and S5a–
b).
In addition to TWF1, VIM is another EMT-related cytoskeleton gene that is inhibited by
miR-30c, as shown by microarray and western blot analyses (Fig. 3a and 3c).
Overexpression of VIM reversed the drug sensitivity caused by miR-30c (Supplementary
Fig. S7a), suggesting that VIM is an important target of miR-30c and may partially overlap
with the effect of TWF1 in regulating drug resistance. However, knockdown of VIM is not
sufficient to mimic the functions of miR-30c or increase drug sensitivity (Supplementary
Fig. S7b).
IL-11 is a downstream target of miR-30c and TWF1
Interleukins (ILs) and cytokines, including IL-6 family members, have been shown to
contribute to drug resistance in breast cancer and other cancers20–23. Based on the
microarray (SAM) analysis, we observed that miR-30c suppressed expression of IL-11, one
of the IL-6 family members, in breast cancer cells (Fig. 3a; see also Supplementary Dataset
1). The specific regulation of IL-11 expression by miR-30c was validated by real-time PCR
analyses, demonstrating both an inhibitory effect of miR-30c oligos and a promoting effect
of anti-miR-30c on IL-11 expression in MDA-MB-231 cells (Fig. 5a).
To determine the role of IL-11 in the miR-30c pathway, we also performed functional rescue
studies by modulating IL-11 expression levels and functions. Overexpression of IL-11
reversed miR-30c–mediated drug sensitivity of MDA-MB-231 cells to doxorubicin and
paclitaxel (Fig. 5b). In addition, we examined the effect of a neutralizing antibody to human
IL-11 on drug response of MDA-MB-231 cells. The anti-IL-11 IgG added to culture media
indeed copied the function of miR-30c by sensitizing cells to the doxorubicin treatment (Fig.
5c), suggesting that the secreted form of IL-11 plays a role in mediating drug resistance.
Similarly, siRNA-mediated knockdown of IL-11 sensitized the response of MDA-MB-231
cells to paclitaxel (Fig. 5d).
Based on Geneset2miRNA target gene predictions, IL-11 was not on the list of predicted
direct targets of miR-30 (Supplementary Table S6), suggesting that it may be a secondary
target of miR-30c. We therefore explored the regulatory link between miR-30c and IL-11.
Since actin affects the activity of myocardin-related transcription factors (MRTFs) and
serum response factor (SRF), which regulate expression of IL-1124, we hypothesized that
TWF1, also an upstream regulator of actin dynamics, regulates IL-11 expression. We
therefore examined the effect of modulated TWF1 on IL-11. As anticipated, siRNA-
mediated knockdown of TWF1 inhibited IL-11 mRNA and protein expression in MDA-
MB-231 cells, similar to the effect of miR-30c on IL-11 (Fig. 5e–f). These data suggest that
IL-11 is an important target of TWF1 in the miR-30c signalling pathway, which regulates
breast cancer chemo-resistance.
We then examined whether IL-11 also regulated F-actin formation. Indeed, knockdown of
IL-11 displayed a MET phenotype very similar to that of miR-30c or knockdown of TWF1,
as demonstrated both by F-actin staining and by counting of vinculin-stained focal adhesions
(Fig. 5g; see also Supplementary Fig. S4 and S5a–b).
miR-30c regulates chemo-resistance in vivo
To validate the role of miR-30c as a regulator of breast tumour progression in vivo, we
examined the effects of miR-30c precursor expression on chemo-resistance, using triple
negative human breast tumour xenograft models generated from breast tumour-initiating
cells (BTICs)25. To facilitate the monitoring of miR-expressing cells in vivo, we cloned the
miR-30c precursor into a lentiviral vector (pFU-miR-30c–PGK-L2G) that co-expresses the
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dual-reporter luciferase gene Luc2-eGFP (L2G) in transduced cells. Based on
bioluminescence imaging following orthotopic transplantation, miR-30c precursor
expression did not alter BTIC-mediated tumour growth in vivo (Supplementary Fig. S8a–b).
At a dose of 1mg/kg, doxorubicin did not inhibit tumour growth mediated by BTICs
expressing the empty L2G vector control but did significantly inhibit the growth of
L2G-30c–expressing tumour cells (n=20, p≤0.00001) (Fig. 6a). This result indicates that
expression of the miR-30c precursor reversed the resistance of the human breast tumour
model to doxorubicin treatment in vivo.
To examine the functional relevance of downstream signalling pathways in vivo, we
measured the expression levels of target genes in sorted breast cancer cells. Compared to
vector L2G–transduced cancer cells, inhibition of TWF1 and IL-11 expression was
confirmed in sorted miR-30c–expressing human breast tumour cells isolated from tumour
models in vivo (Fig. 6b). Furthermore, the reduction of TWF1 expression at the protein level
was confirmed in miR-30c–expressing tumours by immunohistochemical staining (Fig. 6c).
These studies convincingly demonstrated that miR-30c regulates the downstream TWF1 and
IL-11 targets and signalling pathways in vivo.
GATA3 regulates miR-30c expression in breast cancer
To investigate mechanisms by which miR-30 is down-regulated in Group One breast
tumours, we examined possible regulation by transcription factors. JASPAR online analysis
(jaspar.genereg.net)26 identified predicted transcription factor (TF) binding sites in the
putative miR-30c promoter regions, including GATA3 binding sites (Supplementary Table
S7). TF-miRNA association analyses showed that GATA3 mRNA expression levels
correlated with miR-30c expression levels in breast tumours (UC set, n=44, p=0.023) (Fig.
7a); a separate Oxford breast tumour dataset showed a similar correlation6 (n=210, p<0.001)
(Fig. 7a). In addition, forced expression of wild-type GATA3 induced a significant increase
(8–9 fold) of miR-30c expression in GATA3-deficient MDA-MB-231 breast cancer cells
(n=6, p= 1.95E-08) (Fig. 7b). These data indicate that GATA3 regulates miR-30c in breast
tumours.
To determine whether GATA3 binds directly to the miR-30c promoters (30c1 and 30c2), we
performed chromatin-immunoprecipitation (ChIP) assays with anti-GATA3 antibodies
(Santa Cruz) using lysates of MCF-7 cells that express endogenous GATA3 and lysates of
MDA-MB-231 cells that contain ectopically expressed GATA3. By ChIP and real-time PCR
analyses, we observed an interaction between GATA3 with the 30c2 promoter, which
contains two predicted binding elements in both cell lines and an interaction between
GATA3 and the 30c1 promoter in MDA-MB-231 cells (Fig. 7c–d). These data collectively
demonstrate that GATA3 transcriptionally regulates miR-30c expression in breast tumour
cells.
The importance of miR-30c in a clinically relevant pathway
To validate the importance of the miR-30c signalling transduction pathway in clinical
tumours, we examined the association of miR-30c with its target genes. Based on the Oxford
breast tumour dataset 6 with combined mRNA and miRNA expression profiles, we observed
a negative correlation between miR-30c and IL-11 expression (Fig. 8a, n=210, p=0.005). In
the recently completed Breast Cancer dataset in The Cancer Genome Atlas (TCGA) 27, we
also verified inverse correlations between miR-30c and TWF1 and between miR-30c and
IL-11 (Supplementary Table S8, n=521, p=0.0077 and 0.0002, respectively).
In addition, relapse-free analysis with and without adjustment for nodal status, ER, grade,
treatment, and tumour stage demonstrated that IL-11 is strongly associated with clinical
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outcome in three independent breast tumour sets (UNC337, Oxford tumour set, and UC
tumour set) for which IL-11 is a poor prognostic marker (Fig. 8b; see also Supplementary
Table S9).
The above data suggest a signalling network (Fig. 8c) that links miR-30c with its upstream
transcription factor GATA3 and with its downstream targets TWF1 and IL-11 and
demonstrates the clinical importance of the miR-30c regulated pathway in human breast
cancer.
Discussion
Our results implicate miR-30c as a phenotypic regulator of chemo-resistance. While our
studies focus on the role of miR-30c as a regulator of chemotherapy response in breast
tumours, miR-30 expression has been correlated with endocrine therapy resistance, which is
often linked to chemotherapy resistance in advanced oestrogen receptor positive breast
cancer9.
EMT (VIM expression) has been linked with breast tumour initiating cell resistance to
endocrine therapy and chemotherapy2. Our data demonstrate that miR-30c regulates breast
cancer chemo-resistance and EMT (F-actin formation) by direct targeting of the
cytoskeleton gene TWF1 as well as by indirect targeting of the cytokine IL-11. While TWF1
is known to play a significant role in regulating cancer cell chemo-resistance 12, the
underlying mechanisms are not known. We have identified IL-11 as a relevant downstream
target of TWF1 and demonstrated novel roles for TWF1 and IL-11 in regulating F-actin
formation, an EMT marker. IL-11 belongs to the IL-6 family, which have been associated
with drug sensitivity in various cancers and epithelial tissues 21,23,28. Interestingly, TWF1
regulates the expression of IL-11 at both the mRNA and protein levels, although the detailed
mechanisms remain to be elucidated. Since TWF1 is an actin-binding protein, it is likely that
TWF1 regulates IL-11 through sequestering actin monomers, thereby reducing the free actin
monomer pool. A reduced actin monomer pool could release actin-bound myocardin-related
transcription factors (MRTFs), especially MRTFA, from trapping, thereby activating
MRTFs for nuclear translocation24,29. Activated MRTF binds to and assists serum response
factor (SRF) to trans-activate IL-11 transcription, as MRTFA−/− cells display reduced IL-11
expression levels24.
It is of great interest to explore regulatory mechanisms of aberrantly expressed miRNAs in
breast cancer. Our studies have identified GATA3 as a transcriptional regulator of miR-30c.
GATA3 plays an important role in both normal mammary development and breast tumour
differentiation, and its expression correlates with luminal epithelial phenotype and ER
status30–32. MiR-30c promoter analyses also show predicted binding sites for other
transcription factors (e.g. YY1 and BRCA1) that may contribute to the regulation of
miR-30c expression. However, we did not observe significant correlation between YY1 and
BRCA1 expression and miR-30c in the UC tumour set (data not shown). In addition to
transcriptional regulation, other mechanisms can contribute to deregulated miRNA
expression, such as chromatin deletions/amplifications, translocations, promoter silencing,
and deficient post-transcriptional processing. In a separate study, we observed copy number
variation (CNV) at chromatin regions containing miR-30c1 and miR-30c2 genes33.
In conclusion, we have identified a novel miRNA-mediated pathway that regulates chemo-
resistance in breast cancer. The components of this pathway, including GATA3, miR-30c,
TWF1, and IL-11, represent attractive targets for developing new therapeutic strategies in
the management of breast cancer.
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All experiments were performed under the approval of the Institutional Biosafety
Committee, Institutional Review Board and the Administrative Panel on Laboratory Animal
Care of University of Chicago. All experiments had multiple replicates.
Breast tumour arrays and subtypes
Total RNAs were extracted from frozen tissues and cultured cells for DNA microarrays
(Agilent Technologies) as described34. All microarray and patient clinical data are available
at UNC Microarray Database (https://genome.unc.edu) and in the Gene Expression Omnibus
(GEO) under accession number GSE22049 (clinical tumour/tissues) and GSE32617 (MDA-
MB-231 cells). Breast tumours subtype determination was based on gene expression
(PAM50 5-subtype predictor7 and claudin-low predictor35) as well as immunohistochemical
staining for ER, PR, HER2, EGFR, CK5/6, and CK8/1836.
miRNA expression arrays
miRNA arrays, deposited in GEO under accession number GSE39543, were performed for
frozen primary breast specimens (n=51) by Exiqon (Woburn) using the miRCURY™
Hy3™/Hy5™ power labelling kit and the miRCURY™ LNA Array (v.10.0; 757 human
miRs). The expression values are log2 (Hy3/Hy5) ratios. Unsupervised hierarchical
clustering of miRNAs was performed34.
miRNA association tests
Log2-transformed miRNA levels were used in the miR-phenotype and miR-gene association
tests. Expressions of miRNAs across breast tumour subtypes were compared using analysis
of variance (ANOVA). P values were calculated using permutation test. For chemo-
resistance association analysis, AUC (the area under the survival-concentration curve) was
calculated by “ ”. A linear correlation test with Log 2 transformed values of
AUC (or % survival) and miRNA levels were applied in the association test using R
software. The correlations between genes and miRNA-30c expression were interrogated in
the UC breast tumour set (n=44) and The Cancer Genome Atlas (TCGA) Breast Cancer
dataset (n=521 breast samples)27. The normalized gene (“BRCA.exp.547.med.txt”) and
miRNA (“BRCA.780.precursor.txt”) expression matrixes were used as provided in the
TCGA portal (http://tcga-data.nci.nih.gov/docs/publications/brca_2012/). Pearson’s
correlation coefficients were then determined between the expression of each gene and
miRNA-30c (“hsa-mir-30c.MIMAT0000244”).
RNA extraction and real-time PCR
Total RNAs for array analysis were extracted using Trizol (Invitrogen) and RNAeasy mini
kit (Qiagen) or RNA was precipitated with isopropanol and glycogen (Invitrogen). RT- PCR
for miRNAs/genes used individual miRNA/gene Taqman primers (Applied Biosystems).
RNU44 and U6 primers were used for miRNA internal controls and GAPDH for a
housekeeping gene control.
Vectors and cloning
A lentiviral gateway vector pFU-attr-PGK-L2G was constructed based on pFU-L2G25 and
subcloned with miRNA precursor entry clones using LR clonase II (Invitrogen). Human
TWF1 cDNA was subcloned into pDEST40 (Invitrogen) from a donor vector (ORFeome
collection, the University of Chicago). Human IL-11 and GATA3 (transcript variant 2)
expression vectors were purchased from Origene. Luciferase vector containing the 3’UTR of
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TWF1 was obtained from Switchgear Genomics. A site directed mutagenesis kit
(Stratagene) with appropriate primers (IDT) was used to mutate miR-30-binding sites.
Cell culture and transfections
Cells were maintained in DMEM (MDA-MB-231, MCF7, and Hek293T with G418) or
EMEM (BT-20) with 10% fetal bovine serum (FBS) + 1% Penicillin-Streptomycin.
MiRNAs (Dharmacon, negative control #4), anti-miRNAs (Exiqon, negative control A) and
siRNAs (pooled) (Dharmacon) were transfected using Dharmafect (Dharmacon) at 100nM
(MDA-MB-231) or 50nM (BT-20, Hek293T) and repeated on the following day. 3’UTR
luciferase vectors and cDNA vectors were transfected using Fugene (Roche-Promega). For
target gene rescue experiments, cells were transfected twice with cDNA vectors after two
six-hour miRNA transfections.
Cell growth assays
Transfected cells were plated in phenol red free media. Next day calcein AM (Invitrogen)
was added to the wells at 4 µg/µl and incubated for an hour at 37°C. Plates were read at
485/535 nM on the Wallac 1420 plate reader (Perkin Elmer).
Western blot
Cells were harvested 48 hours after transfections, lysed and sonicated in RIPA buffer. 100
µg of protein was loaded onto 4–20% gradient gels for immunoblots with antibodies to
TWF1 (Genetex, GTX11439), Vimentin (Abcam, ab61780), SNAI2 (Cell signalling #9585),
and β-Actin (Sigma-Aldrich, AC-15). Blots were read on Odyssey (Li-Cor).
Interleukin protein level measurement
Cell culture media were collected 36 hours post transfections. IL protein levels in the
supernatants were measured using human cytokine magnetic beads and detection kit
(Millipore) and read by Bioplex (BioRad).
Luciferase assay
Hek293T cells were transfected with miRNAs followed by transfection overnight with
3’UTR luciferase and control renilla vectors (Promega). Cells were lysed 48 hours later and
measured using a dual luciferase kit (Promega). The luciferase signal was normalized to
renilla.
Drugs, cytotoxicity and apoptosis
Paclitaxel and doxorubicin were obtained from either Chemopharmacy at the University of
Chicago or Sigma. Breast cancer cells (ATCC) were treated for 72 hours with doxorubicin
(0 to 1000 nM) and paclitaxel (0–10 nM). Cytotoxicity was measured using AlamarBlue
(Invitrogen). Survival of cells were measured using cell titer blue (Promega) after 72 hours
(MDA-MB-231) or 48 hours (BT-20) treatment. Anti-IL-11 neutralizing antibody (R&D
systems) was added at 12ug/ml before treatment. One day post transfection, cells were
exposed to doxorubicin (100 nM) and paclitaxel (10 nM) for 24 hours and collected for
fixation in 70% ethanol and staining with propidium iodide (Sigma). DNA content was
analysed using BD LSRII flow cytometer.
Immunofluorescence, histology, and microscope
Transfected cells were plated on microscope slides (Millipore) for F-actin and focal
adhesion staining. Cells were fixed in 4% paraformaldehyde/PBS, washed, and stained with
fluorescent phalloidin (Invitrogen F432) and SlowFade Gold antifade reagent with DAPI
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(Invitrogen) or anti-vinculin (ab18058-abcam). Secondary antibody was anti-mouse Texas
Red (T-862-invitrogen). Cell images were taken using Axiovert 100tv (fluorescent),
Axiovert 200M (phase contrast) (Zeiss) or Olympus spinning disc confocal microscope.
Focal adhesions were quantified using ImageJ software with 50 cells counted per well.
Tumour and lung samples were fixed in 10% neutral buffered formalin, embedded, and
sectioned. Immunohistochemical staining was performed using GFP (Cell Signaling, #2956)
and hTWF1 (GeneTex, GTX11439) antibodies at Histology facility. Images were taken by
Pannoramic Scan Whole Slide Scanner (CRi, Cambridge Research and Instrumentation).
Chromatin-immunoprecipitation (ChIP)
GATA3 antibodies (Santa Cruz, cat# 268 for MDA-MB-231 cells, cat#269 for MCF-7 cells)
were used for ChIP according to the EZ ChIP™ Chromatin Immunoprecipitation Kit
(Millipore Upstate Cell Signaling Solutions Catalog #17–371). DNA was purified using a
phenol-chloroform extraction and precipitated by ethanol and glycogen. DNA was
quantified using Fast SYBR Green Master Mix (Applied Biosystems). The sequences of
30c1-P1 primers: 5’ TGTGGGCTGCCTGCTGAATACAC and 5’
AGCAAGAGTGAACTGCTGCCTCCT; and 30c2–P2 primers: 5’
TTTGGAAGGGGTGGGCAGTGAAGA and 5’ ACTGACATGGTCATCCCACTTGC.
Tumour cell isolation and flow cytometer analysis
Xenograft tumours were harvested from mice with 1800 units collagenase III (Worthington)
and 100 Kunitz units DNase I (Sigma) as described25. Dissociated tumour cells were stained
with CD44-APC, H2Kd-biotin and strepavidin-PE-cy7 (BD), and DAPI in HBSS/2% FBS
for further flow analysis or sorting on FacsAriaII (BD).
Lentivirus production and transduction
Second-generation packaging vectors (VPR and VSVG) 25 were used to produce miRNA
precursor lentiviruses, and third-generation packaging vectors (pRSV-rev, VSVG, and
pMDLg/RRE) for other lentiviruses. Viable CD44+ breast cancer cells were isolated from
TN1 xenograft tumours25 and transduced with lentiviruses at 10 or 20 multiplicities of
infection (MOI 10 or 20).
Tumour transplantation and chemotherapy in mice
Tumour cells were mixed 1:1 with Matrigel (BD) and transplanted into NOD/SCID mouse
mammary fad pads (both left 4th and right 4th mammary fat pads)25, with a cohort of 10–20
mice per sample. Doxorubicin was injected intraperitoneally (IP) at 1mg/kg of mouse weight
on day 20 and day 39 post implantation. Tumour growth was measured weekly by
bioluminescence imaging.
Bioluminescence imaging
As described25, bioluminescence images were acquired after D-luciferin (Biosynth AG)
injection to mice (IP, 100 µl at 30 mg/ml per mouse) or incubation (300 µg/ml) with
dissected lungs and tissues, using the IVIS Spectrum® system (Caliper Life Sciences). Data
was analysed using LivingImage 4.0 Software (Caliper Life Sciences) and expressed as total
photon flux.
Statistical Analysis
If not specified otherwise, a student T test was used to evaluate significance, p values and
standard deviations (SD). For animal studies, tumour growth curves were analysed using a
linear mixed model in R software37 with the tumour volume (bioluminescence signals) or its
fold change as a response variable. Lung metastases were analysed using Wilcoxon rank
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sum test. Log transformation was taken on both tumour volume and its fold change. For
predictors, time, group indicator (vector control versus miRNA overexpression, treated
versus untreated), and their interactions were considered initially; then, non-significant ones
were dropped later and only significant variables were kept in the final models. As two
tumours were planted and observed from each mouse, mouse ID (ear tag number) was
included in the model as random effect. To allow autocorrelation among the tumour size
measurements from the same mouse, AR (1) (autoregressive model of order 1) was added to
the error term.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. miRNA profiling of human breast tumours
a. Heat map diagram with two-way unsupervised hierarchical clustering of miRNAs and
breast tumour samples. Each row represents a miRNA and each column represents a sample.
The miRNA clustering tree is shown on the left (Cluster A and B), and the sample clustering
tree appears at the top (Group One and Two). The colour scale shown in the map illustrates
the relative expression level of a miRNA across all samples: red represents an expression
level above the mean; green represents expression lower than the mean. Black means
median expression. Levels of 152 miRNAs passed filtering and shown from 51 frozen
human breast samples (46 breast tumours and 5 normal mammary tissues). NL-normal-like,
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LA-luminal A, LB-luminal B, B-basal-like, H-HER2-enriched, C-claudin-low, U-
undetermined, N-normal (normal breast tissue adjacent to tumours).
b–f. Kaplan-Meier plots of distant relapse-free survival (DRFS) based on the expression of
miR-30 family members (30c, 30a, 30a*, 30b, and 30e*). Associations of miR-30 members
with DRFS were analysed with GSE22216 breast cancer data set (n=210) deposited by
Buffa et al6. To define low (blue) and high (red) expressers, samples were ranked ordered
based on miRNA30 expression and the top 50% samples were defined as high expressers.
Log rank test p values are shown.
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Figure 2. miR-30c corresponds to and regulates chemo-resistance of breast cancer cells
a–b. Association of Log2-transformed miR-30c expression (fold) with the survival (log2-
transformed AUC) of breast cancer cell lines (n=6, T47D, MCF-7, MDA-MB-231, BT20,
HCC70, and HCC38) in response to paclitaxel (Taxol) at 0.1–50 nM (a) and doxorubicin at
1–500 nM (b). A linear correlation test p=0.04 for both association studies.
c. Log2-transformed expression levels of miR-30c in MDA-MB-231 cells 48hrs after oligo
transfections, measured by real-time PCR. P=2.47E-12 by a T test (n=3). Error bars
represent the standard deviation (SD) of the mean.
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d–e. Cell survival of MDA-MB-231 cells after transient transfection of scrambled control
and mature miR-30c oligos, upon 72-hr exposure to different doses of paclitaxel (Taxol, d)
and doxorubicin (Doxo, e). T test p=0.00022 (0.5 nM), 0.00014 (1.0 nM), and 0.00191 (10
nM) for Taxol treatment, and p=0.00802 (10 nM) and 0.00212 (100 nM) for Doxo
treatment, comparing 30c samples to Scr samples (n=6). Error bars: SD.
f. No significant effect of transient transfection of miR-30c on the growth rate of MDA-
MD-231 cells, compared to a mock transfection control and a scrambled RNA mimic
control. Error bars: SD.
g. miR-30c sensitized the drug response of BT-20 breast cancer cells to 48 hr-treatment of
doxorubicin (100nM) and paclitaxel (Taxol, 10nM). When comparing 30c to controls, T test
p=5.52E-07 (mock) and 0.0003 (Scr) for Doxo, p=0.0066 (mock) and 0.0009 (Scr) for Taxol
(n=5). Error bars: SD.
h. Representative flow profiles of BT20 breast cancer cell DNA content upon 24-hr
treatment of paclitaxel (Taxol, 10nM) or doxorubicin (Doxo, 100nM). The gated sub-G1
population represents early apoptotic cells. SD values of the mean are shown.
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Figure 3. miR-30c regulates EMT and directly targets TWF1
a. Genes suppressed by miR-30c in breast cancer cells. Top panel: Left circle shows the
microarray data of 293 genes significantly inhibited by miR-30c in MDA-MB-231 cells (See
Suppl. Table 2). The right circle indicates the genes predicted as direct targets of miR-30c
by Geneset2miR (by ≥4 of 11 algorithms) and overlapped genes are 77 (Suppl. Table 3).
Bottom left panel: Heatmap for 8 anti-apoptotic genes inhibited by miR-30c. Bottom right
panel: Heatmap for predicted direct targets, down-regulated in miR-30c–transfected cells.
Green boxes are color-coded based on log2-transformed expression reduction levels for 4
pairs of 30c/scrambled microarray comparisons.
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b. Expression levels of TWF1 (measured by real-time PCR) upon transfection of miR-30c or
the anti-miR-30c inhibitors into MDA-MB-231 cells. T test p values are shown (n=3). Error
bars: SD.
c. Immunoblots of TWF1 (green band, top panel), VIM (green band, middle panel), SNAI2
(green band, bottom panel) and beta-actin (red band, top panel) with protein lysates of
MDA-MB-231 cells 36hrs after transfections of Mock control, scrambled (Scr), and oligo
miRNA-30c respectively.
d. Effects of miR-30c on cell morphology and F-actin. Top panels: images of MDA-
MB-231 cells after miR-30c transfections. Top left panels: bright field (BF) images of cells
(200x, black scale bars=10µm). Top right panels: fluorescent images (1000x, white scale
bars=5µm) with F-actin staining (green) and DAPI staining of DNA (blue). Bottom
histogram: percentage of round cells counted in two groups, scrambled and 30c–transfected
cells (n=4, counting 4 replicates of 100–150 cells). Cells were harvested 36hrs after
transfections of scramble control (top) or miR-30c oligos (bottom). T test p=0.043. Error
bars: SD.
e. Luciferase activity assays of Hek293T cells co-transfected with miR-30c (or scrambled
control, scr) and the luciferase vector containing wildtype (WT) or mutated (mt) 3’UTR of
TWF1. Mt1, 2, 3 are mutants with G/C converted to T in individual predicted binding site 1,
2, or 3, and mt123 contains all three mutated sites (see Supplementary Fig. S3). T test
p=0.0001 for WT or mt2, comparing 30c to scr control (n=5). Error bars: SD.
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Figure 4. TWF1 is required for miR-30c functions
a. Overexpression of TWF1 reversed the chemo-response sensitized by miR-30c in MDA-
MB-231 cells upon doxorubicin (Doxo) or paclitaxel (Taxol) treatments. T test p=0.01
(Doxo) and 0.02 (Taxol), when comparing 30c/Vec to 30c/TWF1 (n=5). Error bars: SD.
b. Knockdown of TWF1 by a transient transfection of siRNAs of TWF1 (siTWF1)
mimicked the miR-30 overexpression to enhance the cytotoxicity of doxorubicin (Doxo) and
paclitaxel (Taxol) in MDA-MB-231 cells. **p=0.0049, ****p=4.77E-05 (n=5) by a T test.
Error bars: SD.
c. Relative expression levels of TWF1 upon siRNA transfections, measured by real-time
PCR (BD Taqman assays). T test p= 7.31E-05 (n=3). Error bars: SD.
d. Images of F-actin staining of MDA-MB-231 cells inhibited by siTWF1 knockdowns,
compared to scrambled cont-rol (Scr) (1000x, green for F-actin staining and blue for DAPI
staining), white scale bars=5µm. Cells were harvested 36hrs after transfections.
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Figure 5. IL-11 as a downstream target of TWF1
a. Relative IL-11 expression levels measured by real-time PCR analyses. The miR-30c
oligos (mimic) downregulated IL-11 expression whereas the anti-miR-30c inhibitor
upregulated IL-11 expression in MDA-MB-231 cells after 36hrs of transfections, compared
to the scrambled control (Scr). *p=0.03299, ***p=0.00052 (n=3) by a T test. Error bars: SD.
b. Overexpression of IL-11 reversed miR-30c–mediated sensitivity of MDA-MD-231 cells
to doxorubicin (Doxo) and paclitaxel (Taxol) (n=6). T test p=2.8E-05 (Doxo) and 1.1E-04
(Taxol), when comparing 30c/vector to 30c/IL-11. Error bars: SD.
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c. Survival of MDA-MB-231 cells incubated with the goat IgG control or a neutralizing
antibody to human IL-11 (12 µg/ml), upon 72-hr exposure to 100nM doxorubicin (Doxo).
*****p=4.24E-06 by a T test (n=6). Error bars: SD.
d. Knockdown of IL-11 by siRNAs sensitized cytotoxicity of MDA-MB-231 cells to 72-
hour treatment of paclitaxel (Taxol, 10nM). ****p=3.0E-05 by T test (n=6). Error bars: SD.
e. Reduction of IL-11 mRNA expression upon gene knockdowns of siTWF1 and siIL-11,
compared to the scrambled control (Scr) (n=3), measured by real-time PCR. ***p=0.0009
(siTWF1) and 0.0003 (siIL-11) by a T test. Error bars: SD.
f. IL-11 levels detected in the cultured media of MDA-231 cells, upon transfections with
scrambled, miR-30c, and siRNAs for TWF1 or IL-11 (n=4). T test p=0.0381 (30c), 0.0329
(siTWF1), 0.0007 (siIL11) compared to the scrambled control (Scr). Error bars: SD.
g. Images of F-actin staining of MDA-MB-231 cells, transfected with siRNAs of IL-11 and
scrambled control (Scr) (1000x, green for F-actin staining and blue for DAPI staining),
white scale bars=5µm. Cells were harvested 36hrs after transfections.
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Figure 6. miR-30c regulates chemo-resistance of breast tumour in vivo
a. Doxorubicin treatment response (log-transformed bioluminescence signals) of implanted
CD44+ human breast tumour cells expressing L2G vector control (left panel, n=40) and
miR-30c (middle panel, n=40). The right panel pictures are representative bioluminescence
images of treated mice: L2G control (top) and 30c–overexpressed (bottom). Doxorubicin (or
PBS vehicle control for untreated) was given intraperitoneally at 1mg/kg to treated mice on
day 20 and day 39. In the vector control mice (top panel), doxorubicin (red) did not
significantly inhibit tumour growth (slope change after treatment p>0.05, R statistical
package analysis) compared to the untreated group (black). In the miR-30c precursor
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overexpression group (bottom panel), doxorubicin (red) inhibited tumour growth (slope
change p values shown, R model analysis).
b. TWF1 and IL-11 mRNA levels inhibited by pFU-PGK-L2G mediated miR-30c precursor
expression in xenograft breast tumour cells (sorted from human-in-mouse tumors in vivo),
measured by real-time PCR. T test p=0.0001 (TWF1) and 1.04E-07 (IL-11) (n=3). Error
bars: SD.
c. Reduced immunohistochemistry staining against human TWF1 in one of three
representative 30c–overexpressing primary breast tumour sections, compared to L2G–
vector-transduced tumour sections (100x). Scale bars=20µm in both images.
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Figure 7. GATA3 regulation of miR-30c
a. Scatter plots of GATA3 expression and miR-30c levels in UC set breast tumors (n=44,
p=0.023, R=0.341) (left panel) and Oxford breast tumour sets (GSE22220 and GSE22216)
(n=210, p=0.0005, Pearson correlation=0.31) (right panel). Linear regression analyses were
performed between miRNA expression and GATA3 levels after log 2 transformation. Plots
were drawn using the scatterplot function found in the Car package (http://cran.r-
project.org).
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b. Induced expression of miR-30c (T test p=1.95E-08, n=5) by ectopic GATA3 in MDA-
MB-231 breast cancer cells, measured by real-time PCR, compare to the vector control.
Error bars: SD.
c. −3kb promoter regions of hsa-miR-30c1 and 30c2 with predicted GATA3 binding
elements (E0 for 30c1, E1 and E2 for 30c2). PCR primers were designed to amplify the
regions flanking E0 (P1) or both E1 and E2 (P2).
d. Left panel: the miR-30c promoter regions of 30c1 and 30c2 enriched by GATA3
antibody-mediated chromatin-immunoprecipitation (ChIP) with GATA3-overexpressing
MDA-MB-231 lysates, detected by real-time PCR using primers P1 and P2 respectively.
Right panel: the miR-30c2 promoter enriched by GATA3 antibody-mediated ChIP with
MCF-7, detected by real-time PCR with P2 primers. T test p= 0.0004 (30c1) and 3.59E-06
(30c2) for MDA-MB-231 cells, and 5.23E-06 (30c2) for MCF-7 cells respectively (n=6).
Error bars: SD.
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Figure 8. Clinical relevance of the miR-30c signalling pathway
a. Scatter plots between IL-11 single gene expression and the expression of miR-30c in
breast cancer dataset with combined expression profiles of mRNA GSE22220 and miRNA
GSE22216 (n=210). Pearson correlation was estimated (p=0.005).
b. Survival outcomes of IL-11 gene expression in primary breast cancers in the UNC337
publicly available microarray data set 8. Relapse-free survival KM plots were based on
IL-11 gene expression and median gene expression was used to define low and high
expressers (p=0.000109, n=337).
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c. Signalling pathway scheme GATA3-miR30-TWF1-IL-11 regulation of breast cancer
chemo-resistance.
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